top of page

Dr. Von Hoff's Biography

Dr. Daniel Von Hoff, M.D., F.A.C.P.
Clinical, Scientific and Drug Development Advisor

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief, Distinguished Professor Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research.  He is the Medical Director of Research at McKesson Specialty Healthcare and the Scientific Medical Officer for US Oncology Research and leader of the Translation Oncology Program (TOP) specializing in phase I clinical trials done in the US Oncology Research network. Dr. Von Hoff is also currently the Senior Consultant-Clinical Investigations for City of Hope.  He also holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.


Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory.  During his 40 year career he has performed the phase I trials on more than 350 new anticancer agents.  He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including:  mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegibm nab-paclitaxel, nal-IRI, and others.  At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.


Dr. Von Hoff has published more than 720 papers, 142 book chapters and over 1160 abstracts.  Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.  He recently was awarded the Onclive 2016 Giants in Cancer Care award as well as a Gold Medal from his Alma Mater Columbia University for “Excellence in Clinical Medicine”


Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.  He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia).  Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop.  Dr. Von Hoff is the leader of the SU2C Pancreatic Dream Team. He did his post-doctoral training at The Salk Institute for Biological studies. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows. 

Michael Slater's Biography

Dr. Joshua Rabinowitz

Michael Slater
Global Regulatory Advisor

Mr. Michael Slater has more than 35 years of regulatory experience including hands-on preclinical and clinical regulatory strategy development from pre-investigational new drug (IND) application through drug marketing approvals. He has been a part of more than 100 IND filings and 14 successful marketing approvals during his distinguished career. 

Mr. Slater was the Head of Regulatory Affairs and later, Development Operations at Merrimack Pharmaceuticals from 2010 to 2019. At Merrimack, Mr. Slater led the regulatory strategy resulting in the 2015 U.S. NDA approval of Onivyde® (irinotecan liposome injection), an orphan drug for the treatment of metastatic pancreatic cancer. In addition, he worked with Baxalta who acquired certain ex-US rights to Onyvide, to achieve approval in Europe and other countries.

Prior to Merrimack, Mr. Slater held various regulatory roles in several biotech and pharmaceutical companies, including Millennium Pharmaceuticals, Acusphere, Inc., Anika Therapeutics, Inc., ImmuLogic Pharmaceuticals, Biogen and Hoechst Marion Roussel. With a background in applied biology, Mr. Slater also holds a B.Sc. in information science from Leeds Beckett University, U.K. and was a Fellow of The Organization for Professionals in Regulatory Affairs.

Dr. Moyo's Biography

Untitled design-98.png

   Ms. Friday's Biography

Dr. Victor Moyo
Science and Medical Advisor

Dr. Moyo is a highly experienced physician researcher and drug developer, with extensive clinical research pharmaceutical industry experience. He has held a variety of senior leadership positions with responsibility for a number of clinical development plans, IND filings, NDA filings, post-market development plans, notably including his work on such programs as Onivyde® for metastatic pancreatic cancer, epoetin alpha trial in myelodysplastic syndrome, and the Doxil® trial in advanced ovarian cancer. He is also a named inventor on numerous granted patents and patent applications.

Dr. Moyo joined Onconova as Consulting Chief Medical Officer in August, 2023. He has also held various leadership roles as Vice President of Clinical Investigations at Merrimack Pharmaceuticals and the Centocor Ortho Biotech Services, LLC division of Johnson & Johnson.

Dr. Moyo earned his M.D. from the University of Zimbabwe. Following his move to the U.S., he went on to complete his internship and residency in Internal Medicine at the George Washington School of Medicine and Health Sciences and his fellowship in Hematology and Oncology at the Johns Hopkins University School of Medicine.

bottom of page